Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,250 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $20.41, for a total transaction of $66,332.50. Following the sale, the chief financial officer now owns 13,000 shares in the company, valued at $265,330. This represents a 20.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.52, for a total transaction of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total transaction of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock opened at $19.92 on Wednesday. The company has a market cap of $973.27 million, a PE ratio of -10.48 and a beta of 1.03. The company has a fifty day moving average price of $21.93 and a two-hundred day moving average price of $23.94. Enliven Therapeutics, Inc. has a 12 month low of $10.90 and a 12 month high of $30.03.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC boosted its holdings in shares of Enliven Therapeutics by 295.8% during the third quarter. Barclays PLC now owns 56,217 shares of the company’s stock valued at $1,435,000 after acquiring an additional 42,012 shares during the period. First Turn Management LLC boosted its holdings in shares of Enliven Therapeutics by 29.5% during the third quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after acquiring an additional 121,849 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Enliven Therapeutics by 9.9% during the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock valued at $19,164,000 after acquiring an additional 67,813 shares during the period. Ally Bridge Group NY LLC acquired a new position in shares of Enliven Therapeutics during the third quarter valued at $5,998,000. Finally, Patient Square Capital LP acquired a new position in shares of Enliven Therapeutics during the third quarter valued at $2,313,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ELVN. Robert W. Baird raised their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. BTIG Research began coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.